ESC 365 - Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis

ESC Professional Premium Access

Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis

Session: Medical management and risk factors

Topic: Pharmacotherapy

Speaker: Doctor M. Evans (Cardiff, GB)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Marc Evans

Cardiff (United Kingdom of Great Britain & Northern Ireland)

1 follower

4 more presentations in this session

Predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based cohort study

Speaker: Mr T. Lee (Hong Kong, HK)

Celiprolol to prevent arterial events in patients with vascular Ehlers-Danlos and neither symptomatic nor silent arterial event. A retrospective cohort study from the French national reference center

Speaker: Professor T. Mirault (Paris, FR)

Inequalities in accessing quality healthcare, does insurance play a role? retrospective analysis of aortic emergencies from national inpatient sample 2019.

Speaker: Doctor S. Vohra (New Brunswick, US)

Four-month treatment with long-acting glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose co-trasporter-2 inhibitors (SGLT-2i) improves vascular function in type 2 diabetes mellitus

Speaker: Doctor I. Ikonomidis (Athens, GR)

Access the full session

Medical management and risk factors

Speakers: Doctor M. Evans, Mr T. Lee, Professor T. Mirault, Doctor S. Vohra, Doctor I. Ikonomidis

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources